MedTrace Logo

Acetyl-L-Carnitine in the Treatment of Septic Shock

NCT00592488 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-12-08

Study results available
· View outcomes & findings →

Summary

This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.

Conditions

  • Septic Shock

Interventions

DRUG

Acetyl-L-Carnitine

Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Todd W. Rice, MD, MSc · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00592488 on ClinicalTrials.gov